Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Advances in Surgeryarrow_drop_down
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
Advances in Surgery
Article . 2012 . Peer-reviewed
License: Elsevier TDM
Data sources: Crossref
versions View all 2 versions
addClaim

Current Treatment of Papillary Thyroid Microcarcinoma

Authors: Xiao-Min, Yu; Ricardo, Lloyd; Herbert, Chen;

Current Treatment of Papillary Thyroid Microcarcinoma

Abstract

PTMC is being diagnosed with increasing frequency and generally has an excellent prognosis with less than 0.5% disease-specific mortality. Better prognostic stratification, especially for high-risk patients, helps to optimize surgical care. Older age, extrathyroidal invasion, lymph node involvement, and distant metastases are usually regarded as the most potent risk factors for patients with PTMC. Total or near-total thyroidectomy is advocated as the initial therapy for most primary PTMCs, whereas neck dissection is only recommended with the presence of cervical lymphadenopathy or T4 tumors. ATA suggests that postoperative RAI ablations be administrated to patients with gross extrathyroidal invasion or distant metastases. RAI ablation may also facilitate the use of serum Tg concentrations for postoperative risk assessment.

Related Organizations
Keywords

Ploidies, Thyroid Cancer, Papillary, Lymphatic Metastasis, Biopsy, Fine-Needle, Carcinoma, Humans, Neoplasm Invasiveness, Thyroid Neoplasms, Prognosis, Carcinoma, Papillary

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    19
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Top 10%
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Top 10%
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Top 10%
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
19
Top 10%
Top 10%
Top 10%
Related to Research communities
Cancer Research
Upload OA version
Are you the author of this publication? Upload your Open Access version to Zenodo!
It’s fast and easy, just two clicks!